Here are the DEF 14A proxy statements from Actuate Therapeutics, Inc. (ACTU) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ACTU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACTU filings page.
Actuate Therapeutics, Inc. is holding its 2026 virtual annual meeting of stockholders on May 21, 2026 at 11:00 a.m. EDT to elect two Class II directors and ratify Crowe LLP as independent auditor for 2026.
Stockholders of record as of March 24, 2026, holding 23,704,691 common shares, may vote online, by phone, mail or during the webcast. The proxy also details corporate governance practices, committee structures and 2025 executive pay, including salary, cash bonuses and equity awards under the 2024 Stock Incentive Plan.